COVID-19 is a novel coronavirus infection caused by respiratory droplets and contact transmission. With the spread of the epidemic, it has become a serious threat to global public health. China has launched a full range of vaccination including the third dose of homologous and sequential booster immunization. To further improve COVID-19 vaccine immunization strategy, we start the clinic research about sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine in Zhejiang province.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
200
One dose COVID-19 vaccine
Xihu District Center for Disease Control and Prevention
Hangzhou, Zhejiang, China
RECRUITINGIncidence of adverse reactions (AR) in 0-14 days after immunization
Incidence of adverse reactions (AR)
Time frame: 14 days
Geometric mean titer (GMT) of neutralizing antibody against SARS-COV-2 at 14 days after immunization
Geometric mean titer (GMT) of neutralizing antibody against SARS-COV-2
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.